Administration of vvDD-IL15/Rα immunotherapy to significantly improve the quantity and quality of tumor-specific T cells, reactive against a diverse arrangement of tumor antigens for ex vivo expansion and autologous transfer would represent a critical advancement in this therapeutic strategy, and greatly expand the number of patients responsive to TIL therapy. This evidence concerns the gene IL15 and neoplasm.